BGMSP
Apollo Global Management, Inc.
NASDAQ · Healthcare · Medical - Pharmaceuticals · US
$1.10
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 36.0B | 32.0B | 43.0K | 420.0K | — |
| Cost of Revenue | 5.6B | 1.4B | — | — | — |
| Gross Profit | 30.4B | 30.6B | 43.0K | 420.0K | — |
| Operating Expenses | |||||
| R&D Expense | — | — | 6.7M | 19.2M | 20.3M |
| SG&A Expense | 3.9B | 3.1B | 5.4M | 6.7M | 7.4M |
| General & Admin Expense | 2.9B | 3.1B | 5.4M | 6.7M | 7.4M |
| Selling & Marketing Expense | 927.0M | — | — | — | — |
| Other Expenses | 17.8B | 19.3B | — | — | — |
| Total Operating Expenses | 21.7B | 22.3B | 12.0M | 25.9M | 27.7M |
| Cost and Expenses | 27.3B | 23.8B | 12.0M | 25.9M | 27.7M |
| Operating Income (EBIT) | 8.7B | 8.3B | (12.0M) | (25.5M) | (27.7M) |
| Non-Operating | |||||
| Interest Income | 5.9B | 131.0M | 12.0K | 266.0K | 210.0K |
| Interest Expense | 433.0M | 370.0M | — | — | — |
| Net Interest Income | 5.5B | (239.0M) | 12.0K | 266.0K | 210.0K |
| Other Non-Op Income/Expense | (1.3B) | (1.6B) | 10.0K | (98.0K) | 1.7M |
| Non-Operating Income (excl Interest) | 824.0M | 1.2B | — | — | — |
| EBT (Pre-Tax Income) | 7.4B | 6.7B | (12.0M) | (25.6M) | (25.9M) |
| Income Tax Expense | 3.1B | 1.3B | (782.0K) | (3.0M) | (4.7M) |
| Bottom Line | |||||
| Net Income | 1.9B | 3.5B | (11.2M) | (22.6M) | (21.2M) |
| Earnings from Cont. Ops | 4.3B | 5.4B | (11.2M) | (22.6M) | (21.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 1.2B | 2.1B | (11.2M) | (22.8M) | (21.4M) |
| Per Share | |||||
| Basic EPS | $4.62 | $5.58 | $0.00 | $0.00 | $0.00 |
| Diluted EPS | $4.47 | $5.54 | $0.00 | $0.00 | $0.00 |
| Revenue Per Share | $60.73 | $52.72 | — | — | — |
| Shares | |||||
| Basic Shares Outstanding | 592.0M | 607.9M | — | — | — |
| Diluted Shares Outstanding | 610.0M | 607.9M | — | — | — |
| Profitability Metrics | |||||
| EBITDA | 9.5B | 8.5B | (12.0M) | (25.4M) | (27.6M) |
| D&A | 1.6B | 1.4B | 6.0K | 31.0K | 32.0K |
| EBIT | 7.9B | 7.0B | (12.0M) | (25.5M) | (27.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026